The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

Table 3

Associations between demographic, clinical and laboratory variables of familial Mediterranean fever rilonacept study participants and physical/psychosocial health-related quality of life.

	Physical score	Psychosocial score
Correlation coefficients
Attack frequency	𝑟=−𝟎.𝟒𝟔; 𝑃=𝟎.𝟎𝟐𝟏	𝑟=−0.30; 𝑃=0.14
Proportion of days in attack	𝑟=−𝟎.𝟔𝟖; 𝑃=𝟎.𝟎𝟎𝟎𝟐	𝑟=−𝟎.𝟕𝟑; 𝑃<𝟎.𝟎𝟎𝟎𝟏
Patient global assessment	𝑟=−𝟎.𝟕𝟓; 𝑃<𝟎.𝟎𝟎𝟎𝟏	𝑟=−𝟎.𝟓𝟔; 𝑃=𝟎.𝟎𝟎𝟑
Physician global assessment	𝑟=−𝟎.𝟓𝟔; 𝑃=  0.003	𝑟=−𝟎.𝟒𝟔; 𝑃=𝟎.𝟎𝟏𝟕
Modified Armenian severity score [24]	𝑟=−𝟎.𝟓𝟒; 𝑃=   0.005	𝑟=−0.24; 𝑃=0.24
Low grade fever (37-38)	𝑟=−0.10; 𝑃=0.63	𝑟=0.06; 𝑃=0.76
Medium grade fever (38-39)	𝑟=−0.02; 𝑃=0.93	𝑟=−0.36; 𝑃=0.07
High grade fever (>39)	𝑟=−0.15; 𝑃=0.47	𝑟=−0.10; 𝑃=0.61
Abdominal pain	𝑟=−0.21; 𝑃=0.29	𝑟=−0.02; 𝑃=0.93
Chest pain	𝑟=0.06; 𝑃=0.75	𝑟=−0.06; 𝑃=0.76
Musculoskeletal symptoms	𝑟=0.21; 𝑃=0.30	𝑟=0.13; 𝑃=0.51
Analysis of variance (ANOVA) tests
^∧Age	𝑃=0.45	𝑃=𝟎.𝟎𝟐𝟐
^#Ethnicity	𝑃=0.33	𝑃=𝟎.𝟎𝟐
^†Erythrocyte sedimentation rate	𝑃=𝟎.𝟎𝟏𝟎	𝑃=0.96
^†C-reactive protein	𝑃=0.49	𝑃=0.67
^†Serum Amyloid A	𝑃=0.23	𝑃=0.84
^†Fibrinogen	𝑃=𝟎.𝟎𝟒𝟗	𝑃=0.78
^†Platelets	𝑃=0.17	𝑃=0.65

Continuous variables were analyzed by Spearman’s correlation and categorical variables by analysis of variance.
Significant results are bolded.
∧Age groups included >18 (𝑁=10) and ≤18 years (𝑁=4); ^#Ethnicity groups included Arab Christians (𝑁=4), Armenians (𝑁=5), and others (𝑁=5); ^†Acute phase reactants were dichotomized for analysis as either normal or abnormal.